Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tom Baker Cancer Centre | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators plan to study high dose, single treatment radiation, using a plastic mask instead of a head frame that pins into a patient's skull. The investigators need to (1) quantify set-up accuracy and patient motion during radiation treatment and (2) ensure that without the head frame the tumour control rate and risk of complications are similar to our previous experience using the head frame.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Open Arm | Experimental | Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Frameless Stereotactic Radiosurgery with radiation mask | Device | Linac-based radiosurgery using a thermoplastic mask (single treatment) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quantification of patient movement occurring during treatment. | overall |
| Measure | Description | Time Frame |
|---|---|---|
| Local tumour control | overall | |
| risk of complication (radionecrosis) | overall |
Not provided
Inclusion Criteria:
Exclusion Criteria:
None of the lesions is abutting or within critical neurological structures: *brainstem
The clearance between metastatic lesions and all critical structures must be at least 2 mm.
Patients must not have leptomeningeal disease.
Contraindications to imaging or radiation (e.g. pregnancy, elevated serum creatinine, allergy to contrast agents, severe claustrophobia, metal particles in the eye).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jon-Paul Voroney, Phd. M.D. | Contact | 403-521-3164 | Jon-Paul.Voroney@albertahealthservices.ca |
| Name | Affiliation | Role |
|---|---|---|
| Jon-Paul Voroney, MD | Tom Baker Cancer Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tom Baker Cancer Centre | Recruiting | Calgary | Alberta | T2N 4N2 | Canada |
Not provided
| ID | Term |
|---|---|
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |